APA (7th ed.) Citation

E, F., H, T., P, W., S, G., V, D. P., E, M., . . . RT, K. (2026). Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(14), 3031. https://doi.org/10.1158/1078-0432.CCR-25-4767

Chicago Style (17th ed.) Citation

E, Favours, et al. "Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 32, no. 14 (2026): 3031. https://doi.org/10.1158/1078-0432.CCR-25-4767.

MLA (9th ed.) Citation

E, Favours, et al. "Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 32, no. 14, 2026, p. 3031, https://doi.org/10.1158/1078-0432.CCR-25-4767.